Dr. Srikanth M

• Dr. Srikanth M is a hematologist with experience of 21+ years.


• He has completed MBBS, Diploma and FRC. Plus, he has done Fellowship from Royal Marsden Hospital, UK.


• He is a member of American Society of Hematology, Royal College of Pathologist, British Society of Hematology, European Society of Hematology and Royal College of Physicians. 


• Dr. Srikanth has written many research papers for national and international journals. 

Multiple Myeloma,
Leukemias,
Lymphomas

• Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis. Blood 2010: 408


• Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma. Molecular Cancer Therapy,2009:762-770.


• Srikanth M, Davies F E, Morgan GJ. Update on novel drug combinations in Multiple Myeloma. Expert opinion on Investigational Drugs. 2008;17:1-12. 


• Srikanth M,  Jenner M, Wu  P, Kaczmarek P, Dines S, Saso RM, Ethell M,  M Potter M, Treleaven JG, Davies FE, Morgan GJ  Survival and Outcome of Blastoid Variant Myeloma Following Treatment with DT-PACE. Haematologica. 2007;92:712.


• Davies FE, Srikanth M, Wu P, Jenner M,  McCormack R,  Cordero F, Trudel G, Morgan GJ. The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant clinical activity in relapsed/refractory myeloma patients.  Blood 2007;110:2727.


• Aronson L, Davenport EL, Giuntoli SG, Srikanth M, Smith E, Morgan GJ, Davies FE.

Chennai

India